Nishino, Mizuki
Ramaiya, Nikhil H.
Hatabu, Hiroto
Hodi, F. Stephen
Article History
First Online: 27 June 2017
Competing interests
: M.N. is a consultant for Bristol-Myers Squibb, Toshiba Medical Systems and WorldCare Clinical, and has received research grants from Canon and the Merck Investigator Studies Program, and honoraria from Bayer. H.H. is a consultant for Toshiba Medical Systems, and has received research support from Canon, Konica-Minolta and Toshiba Medical Systems. F.S.H. has served as a non-paid consultant for Bristol-Myers Squibb, has received clinical trial support from Bristol-Myers Squibb, is an adviser and receives clinical trial support from Genentech and Merck, is a consultant for Amgen, EMD Serono and Novartis, and has a patent relating to tumour antigens (issued), and a patent related to the institution of major histocompatibility complex (MHC) class I polypeptide-related sequence A (MICA) as a target (licensed). N.H.R. declares no competing interests.